Monographs Not Viable for Unapproved Prescription Drug Review, FDA Says

A monograph system is not a viable approach for evaluating the safety and efficacy of prescription drugs that are marketed without FDA approval, agency officials told an overflow crowd during a Jan. 9 workshop on unapproved drugs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet